Vivoryon And MorphoSys Link To Accelerate Novel Small Molecule Checkpoint Silencing Approach
Vivoryon CEO explains how QPCTL-targeting small molecule technology will be tested for combination with MorphoSys’s tafasitamab to enhance cancer-killing efficacy.
You may also be interested in...
Skyhawk continues its recent spate of deal-making, using its SkyStar platform in a deal with Genentech, which also is looking into neurology with Convelo. AbbVie buys STING specialist Mavupharma, while Recordati pays Novartis $390m for Cushing’s products.
Morphosys says good L-MIND Phase II data back its plan to submit a US BLA to the US Food and Drug Administration by year-end, for a potential mid-2020 approval of tafasitamab.
Probiodrug is ramping up plans to run Phase IIb Alzheimer's disease trials on the back of biomarker data that indicates that its approach to targeting pyroglutamate-Abeta is a promising therapeutic strategy. CEO Konrad Glund spoke to Scrip at the 2018 Biotech Showcase.